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Dear Editor,
We appreciate the comments by Haag, primarily because
they respond to the main aim of the review we wrote on
MOH: to draw attention and stimulate research on a con-
dition that is severe, disabling, potentially harmful, under-
diagnosed and undertreated [1].
Regarding the selection of papers, it was based, as in
most of the reviews published in the literature, primarily on
objective criteria related to the scientific strength of the
paper.
Increased perception and recognition of MOH as a
severe health condition, promulgated also by the Interna-
tional Headache Society with the identification of MOH as
a separate entity [2], has fostered the diffusion among the
medical community of the virtuous process represented by:
awareness of a disease ? detection/identification of suf-
ferers ? management of the disease. This is happening in
Europe, America, Asia and hopefully elsewhere, and does
not strictly mean that we believe that the number of sub-
jects overusing drugs for acute migraine treatment is
increasing, although this remains a possibility, given the
increased awareness and improved diagnostics potency of
the medical community and the increased availability and
advertisement of drugs.
The focus on Latin American countries was prompted
by the observation, that no figures on MOH in Latin
American countries were available while revising the very
scarce data from the literature on MOH. This findings was
somewhat surprising and worrying because we knew from
the collaboration with our Latin American colleagues and
partners within the Comoestas Project1 that MOH is defi-
nitely an issue in their countries, potentially even bigger,
because of a lessened attention of the health system to the
headache problem and an easier access to OTC drugs and
to herbal derivatives containing ergot derivatives. Given
these premises, we felt that the addition of a paragraph on
the very limited data available on MOH in Latin American
countries (even if partly coming from a preliminary,
unpublished report) would be useful to draw attention on
the issue and to spur further research on the topic.
The paper from Meskunas [3] was amply mentioned
because it represents a good example of a well-done sci-
entific evaluation of a problem and of its persistence,
notwithstanding the dramatic changes in terms of symp-
tomatic drugs endured by headache community in the last
15 years. Haag is right when he suggests, in agreement
with ICHD-II, that MOH results from the interaction of a
drug used in excess and a susceptible terrain, while little
doubt exists as regards the causal role of symptomatic
drugs in the development of true MOH, but discussion of
the etiology and/or pathophysiology of MOH was beyond
the scopes of the review.
As regards the ergotamine preparation, it is still avail-
able on the German market but it is no longer used as
suggested by a large population-based study on 16,500
subjects (Katsarava et al., unpublished data).
Finally, a very limited number of papers have investi-
gated and described MOH in children and adolescents. To
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the best of our knowledge, the 25 young subjects with daily
or almost daily headache and overusing analgesics descri-
bed by Hering-Hanit and Gadot [4] indeed represent the
largest series of MOH in children and adolescents as
confirmed by their improvement following analgesic
withdrawal.
We are thankful to Haag for his criticism, because
criticism is one of the bases for improving scientific
knowledge. In this frame, we have to respect Haag’s per-
sonal judgment but do not accept it because the review was
prepared scrupulously by scientists and headache experts
who did their best to put together the most reliable
knowledge on MOH published in the international litera-
ture. Furthermore, the review was peer-reviewed and
published in a well-known and highly respected headache
journal.
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